DB&C Advisors LLC Invests $4.74 Million in AbbVie Inc. $ABBV

DB&C Advisors LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, HoldingsChannel reports. The firm purchased 20,732 shares of the company’s stock, valued at approximately $4,737,000. AbbVie comprises 5.9% of DB&C Advisors LLC’s portfolio, making the stock its 4th biggest position.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Eclectic Associates Inc. ADV grew its position in AbbVie by 0.8% during the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after buying an additional 45 shares during the period. Weil Company Inc. grew its position in AbbVie by 2.3% during the third quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock worth $469,000 after buying an additional 46 shares during the period. Hardin Capital Partners LLC grew its position in AbbVie by 1.4% during the fourth quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock worth $759,000 after buying an additional 46 shares during the period. Dogwood Wealth Management LLC grew its position in AbbVie by 10.8% during the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after buying an additional 46 shares during the period. Finally, Quantum Private Wealth LLC grew its position in AbbVie by 2.0% during the fourth quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock worth $543,000 after buying an additional 46 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ABBV shares. Evercore set a $235.00 target price on shares of AbbVie in a research report on Friday, May 15th. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a research note on Thursday, April 30th. Piper Sandler increased their price target on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Finally, William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS / drug-cost watchdog, improving access and potential sales in a major international market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
• Positive Sentiment: AbbVie also won European Commission approval for Aquipta to treat migraine, which could expand the drug’s commercial opportunity in Europe. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: AbbVie’s FDA approval of Decnupaz for BPDCN was highlighted as validation of its ADC oncology strategy, reinforcing confidence in the company’s long-term cancer pipeline. Does Decnupaz Approval Validate ABBV’s ADC Strategy in Oncology?
• Positive Sentiment: AbbVie completed a real-world study of upadacitinib in China and finished a bioavailability study for ABBV-932, both of which support ongoing pipeline development. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Neutral Sentiment: AbbVie was also featured in value-stock and “cheap stocks” roundups, which may reflect its appeal to investors but are not direct company-specific catalysts. 5 Best Cheap Stocks to Buy for Beginners June 2026’s Top Stocks Estimated Below Intrinsic Value
• Negative Sentiment: AbbVie ended an early lung cancer trial for ABBV-647, which removes one potential upside driver from the oncology pipeline, though the broader impact appears limited. AbbVie Ends Early Lung Cancer Trial for ABBV-647

AbbVie Trading Up 1.2%

ABBV opened at $227.68 on Friday. The company has a fifty day simple moving average of $209.85 and a 200 day simple moving average of $219.36. The firm has a market cap of $402.27 billion, a price-to-earnings ratio of 112.16, a PEG ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period last year, the business earned $2.46 EPS. On average, analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.